Knee osteoarthritis
The most common indication for regenerative medicine — and the one with the deepest evidence base. Targeted intra-articular protocols for tibiofemoral and patellofemoral OA, alone or alongside conservative care.
- Class
- Cartilage · joint
- Approach
- Intra-articular, image-guided
- Materials
- MSC · exosome · PRP
- Adjunct
- Softwave shockwave
01 About
What knee OA is.
Knee osteoarthritis is the progressive degeneration of articular cartilage in the tibiofemoral or patellofemoral compartments of the knee. It is characterized by cartilage loss, subchondral bone change, synovial inflammation, and reduced joint space — and clinically by pain, stiffness, and progressive loss of function.
The conventional treatment pathway runs from anti-inflammatories and physical therapy to corticosteroid or hyaluronic acid injections to, eventually, total knee replacement. Regenerative protocols sit between conservative care and surgery: an option for patients who have plateaued on the first set of interventions but are not yet — or are not interested in being — surgical candidates.
02 How it works
How stem cells & exosomes support the joint.
Mesenchymal stem cells delivered intra-articularly modulate the inflammatory environment of the joint, signal to surviving chondrocytes, and release exosomes that drive paracrine repair of soft tissue. The clinical effect — reduced inflammation, reduced pain, improved mobility — is reproducible in the literature for mild-to-moderate OA.
We typically combine cellular and exosome material in a single protocol, and pair it with Softwave shockwave when tissue priming improves the response. PRP is sometimes used as a stand-alone alternative for early-stage patients or those preferring an autologous-only approach.
03 What the research shows
What the studies show.
The evidence base for mesenchymal stem cell therapy in knee osteoarthritis is among the strongest in regenerative medicine. Multiple randomized controlled trials and meta-analyses have demonstrated meaningful pain and functional improvements at 12 months, with a favorable safety profile.
-
Treatment of Knee Osteoarthritis With Allogeneic Bone Marrow Mesenchymal Stem Cells: A Randomized Controlled Trial
30 patients with chronic knee OA received either allogeneic bone-marrow MSCs or hyaluronic acid. At 12 months, the MSC group reported significantly greater pain reduction and functional improvement, with MRI showing better cartilage quality (T2 mapping) than controls.
Read on PubMed -
Umbilical Cord-Derived Mesenchymal Stromal Cells for Knee Osteoarthritis: Repeated Dosing vs. Single Dose vs. Hyaluronic Acid
A controlled trial compared single-dose and repeat-dose umbilical-cord MSC therapy against hyaluronic acid in patients with symptomatic knee OA. The repeat-dose MSC group achieved superior pain relief and function scores at 12 months — the strongest signal that protocol design matters.
Read on PubMed -
Efficacy and Safety of Mesenchymal Stem Cells in Knee Osteoarthritis: A Systematic Review and Meta-Analysis
A 2025 systematic review pooling 18 randomized trials found that MSC therapy produced significantly greater pain reduction and functional improvement than placebo or hyaluronic acid at 12 months — with no increase in serious adverse events. The strongest signal in regenerative knee literature to date.
Read on PubMed Central
Evidence is strongest for mild-to-moderate OA (Kellgren-Lawrence grade 2–3). Results in late-stage, bone-on-bone disease are limited — and we'll tell you when surgery is the better answer.
04 Are you a candidate
Who's a candidate. Who isn't.
Candidates:
- Imaging-confirmed mild-to-moderate OA (Kellgren-Lawrence grade 2–3) with persistent pain on activity.
- Patients who have plateaued on PT, NSAIDs, and conservative care.
- Patients who are not yet surgical candidates or wish to delay or avoid joint replacement.
- Active adults pursuing return to sport, hiking, golf, or daily function without long downtime.
When we will not recommend it:
- Bone-on-bone end-stage OA (KL grade 4) where surgery is the more appropriate answer.
- Acute joint infection, untreated coagulopathy, or active malignancy.
- Patients who have not had appropriate imaging — we do not inject blind.
- Patients whose pain on workup is clearly mechanical and surgical rather than degenerative.
Think you might be a candidate?
The first step is a 60–90 minute consultation. We review your imaging, history, and goals — and tell you honestly whether regenerative therapy is the right next step.
05 A patient experience
I was trying to avoid surgery for my knee. The stem cells I got at Apex helped so much — I haven't felt this good in years.
Denise Bradley Google · 5.0
07What happens at your consultation
A conversation, not a sales meeting.
-
01
Intake & history
60–90 minutes. We review imaging, prior treatments, current medications, and goals. Most of this hour is listening.
-
02
Focused exam
A clinical exam tailored to your indication. Range of motion, strength, functional testing — what the literature actually predicts response on.
-
03
Honest candidacy review
If we think you're a candidate, we'll tell you why. If we don't, we'll tell you what we'd recommend instead — surgery, PT, watchful waiting.
-
04
Written plan & pricing
A defined treatment plan with modality, sequence, follow-up cadence, and total cost — before any commitment.
06 What treatment looks like
What treatment looks like.
A typical knee protocol begins with a 60–90 minute consultation, MRI or weight-bearing X-ray review, and targeted labs. Treatment is usually a single in-clinic session — image-guided intra-articular delivery of cellular and exosome material — followed by a defined recovery and follow-up schedule.
Reassessment occurs at three months, six months, and one year, with functional testing and (if indicated) repeat imaging. We adjust the protocol on what we observe — adjunct shockwave, repeat dosing, or a different approach — never on what we hoped for.
09 Common questions
Knee OA, answered.
How is this different from a steroid injection?
Steroid masks pain temporarily; regenerative therapy targets the underlying tissue. Steroid relief typically fades in weeks to a few months and can degrade cartilage over repeated use. Regenerative response builds over 3–6 months and is durable. Some patients use both at different points in their care, but they aren't substitutes.
Will I still need a knee replacement eventually?
Possibly. In mild-to-moderate OA (Kellgren-Lawrence grade 2–3), regen often delays replacement for years and meaningfully improves function. In end-stage bone-on-bone disease (KL grade 4), surgery is usually the better answer — and we'll tell you that honestly rather than treat for revenue.
How many sessions will I need?
Most knee protocols are a single intra-articular session. Depending on imaging, severity, and your response at 3-month reassessment, a follow-up dose may be recommended. The full schedule is defined in writing before any commitment — no open-ended packages.
When will I see results?
Modest improvement in 6–8 weeks. The full response builds over 3–6 months. Cellular biology takes time — we calibrate expectations honestly and track progress at defined reassessment points (3, 6, 12 months) rather than asking you to evaluate too early.
What are the risks or side effects?
The most common short-term side effects are mild post-injection soreness or swelling at the joint for 48–72 hours, easily managed with rest and ice. Serious adverse events are rare across the published RCT data when allogeneic, screened material is used and image guidance is followed. We review your specific risk profile (anticoagulants, autoimmune status, joint history) at the consultation.
Can I keep doing physical therapy during treatment?
Yes — and we recommend it. The strongest published outcomes come from regenerative protocols paired with structured PT. We coordinate timing (light activity for the first 2 weeks, progressive loading thereafter) and communicate with your PT directly when helpful.
10 Coverage & cost
Most regenerative protocols at Apex are not covered by insurance — we discuss pricing directly, in writing, before any commitment. Softwave shockwave is the exception: covered by Medicare Parts A & B with supplement (not by Medicare Advantage). Financing options are available for protocols not covered. We never hold a pricing conversation until we know you're a candidate.
Begin with a consultation.
A 60–90 minute first visit. Imaging review, history, and a frank conversation about whether stem cell and exosome therapy is the right tool for your knee — and what we'd recommend if it isn't.